Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD
Status:
Completed
Trial end date:
2021-10-29
Target enrollment:
Participant gender:
Summary
The primary objective is to provide continued access to subjects who would like to continue
levodopa-carbidopa intestinal gel (LCIG), after completion of an open-label study (S187.3.003
or S187.3.004).
Phase:
Phase 3
Details
Lead Sponsor:
AbbVie AbbVie (prior sponsor, Abbott)
Collaborators:
IQVIA, formerly Quintiles Quintiles, Inc.
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa